百亿主动权益基金仅20只！葛兰、张坤、谢治宇等纷纷“瘦身”！新星张璐夺冠！

Core Insights - The recent market recovery has led to an increase in the number of non-monetary funds exceeding 10 billion yuan, with 226 such funds reported as of the end of Q2, representing approximately 0.98% of the total, an increase of 34 funds from Q1 [4][5] - The number of active equity funds with over 10 billion yuan has stabilized at 20, with the new addition being the "Yongying Advanced Manufacturing Select C" fund managed by Zhang Lu [4][5] - The performance of these large-scale funds has improved significantly this year, with the average return of active equity funds being 14.31%, outperforming the CSI 300 index [5] Fund Performance - As of June 30, the total share of active equity funds was 31.2 trillion shares, a decrease of 129.7 billion shares (approximately 4%) from the end of last year [5] - The top-performing active equity fund this year is "Yongying Advanced Manufacturing Select C," with a return of 57.65% as of August 1, significantly higher than its benchmark return of 9.77% [9] - The largest active equity fund is "E Fund Blue Chip Select," managed by Zhang Kun, with a size of 34.943 billion yuan as of the end of Q2 [5] Key Holdings - The top five holdings of "Yongying Advanced Manufacturing Select C" include companies in the humanoid robot industry, such as Zhejiang Rongtai and Lingyun Shares, indicating a strong focus on this sector [9][10] - The "Zhongou Medical Health A" fund, managed by Guo Lan, has a significant holding in WuXi AppTec, which has seen a price increase of 31.14% since the end of Q2 [11][12] Investment Outlook - Zhang Lu from Yongying Fund emphasizes the importance of production ramp-up in core robotics companies and the supportive domestic policies for the robotics industry in the upcoming quarter [10] - Guo Lan highlights the potential for innovation drugs and structural opportunities in the consumer healthcare sector, particularly in medical aesthetics and home medical devices, as the economy recovers [13][14] - Xie Zhiyu from Xingzheng Global Fund suggests that sectors like innovative drugs, smart driving, and new consumption are more suitable for value investors due to their realistic performance support [17]